05Oct 2023
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis

A study revealed that Efruxifermin, a bivalent Fc–FGF21 analogue, demonstrated efficacy in treating non-alcoholic steatohepatitis (NASH) patients with moderate (F2) or severe (F3) fibrosis. During the 24-week trial, 39% of patients receiving Efruxifermin 28 mg and 41% on Efruxifermin 50 mg showed improvement in fibrosis of at least 1 stage with no worsening of NASH, compared to 20% in the placebo group. These results and acceptable tolerability suggest the potential for Efruxifermin in NASH treatment.

  • #gastroenterology

Like

Save

Share